Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

D. Boral Capital lowered the firm’s price target on Checkpoint Therapeutics (CKPT) to $4.80 from $9 and keeps a Buy rating on the shares. The ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research ...

NEW YORK, March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC ...

Lake Street analyst Thomas Flaten maintained a Buy rating on Checkpoint Therapeutics (CKPT – Research Report) today. The company’s shares ...

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT)’s sale to Sun Pharmaceutical Industries Limited for $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone.

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...

(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...

On March 9, 2023, Checkpoint announced the deal with Sun Pharma, under which shareholders will receive $4.10 per share in cash (or a total of $355 million). if cosibelimab receives EU approval within ...